Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims
Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former executives for misleading claims about the results of Alzheimer's clinical trials.
Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...
On Friday, Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $28.49 which represents a decrease of $-3.38 or -10.61% from the prior close of $31.87. The stock opened at $28.08 and ...
Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...
Following our analysis of the options activities associated with Cassava Sciences, we pivot to a closer look at the company's ...
Many investors had enough of the company and sold off its stock to the point where it lost nearly 11% of its value across the ...
Cassava Sciences (SAVA) stock gains as company strikes consulting agreement with former CEO Remi Barbier. Read more here.
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback